Condition
Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 2 (2)
P 3 (1)
Trial Status
Suspended1
Recruiting1
Not Yet Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07301424Phase 2Not Yet RecruitingPrimary
Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL
NCT07152041Phase 3RecruitingPrimary
Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
NCT01222013Phase 2SuspendedPrimary
Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)
Showing all 3 trials